Lorenzo Dottorini

Geriatric Oncologist at ASST-Bergamo Ovest Treviglio #OldLivesMatter

[Lorenzo Dottorini @lorenzodotto]

Very happy and proud to share our @JCO_ASCO publication. Accordin to our research no advantage in OS and DFS adding oxaliplatin to adjuvant stage III colorectal cancer in older patients.
https://t.co/G3rgj65fWd

[Lorenzo Dottorini @lorenzodotto]

@Crypto_Twittier @PickleLinky 🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡

[Lorenzo Dottorini @lorenzodotto]

@Crypto_Twittier Anche i prezzi delle alt li avevi previsti benissimo.......aspettiamo ancora la tua previsione su Brett.......🤡🤡🤡🤡

[Lorenzo Dottorini @lorenzodotto]

@Crypto_Twittier Ma va caghèr va

[JCO Oncology Practice @JCOOP_ASCO]

Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next.
Co-authored by @faupe.

Read the full article. https://t.co/2WR6KX6BoN
#ImmunoOnc

[Journal of Geriatric Oncology @JGeriOnc]

Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma https://t.co/jvbUJfOAkM @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #Geriatric8 #CGA

[Lorenzo Dottorini @lorenzodotto]

Outstanding results!

[Yakup Ergün @dr_yakupergun]

Oxaliplatin in Stage II–III CRC: Age Matters

🔹 Stage III, ≤70 yrs → OS benefit
🔹 Stage III, >70 yrs → No OS gain
🔹 Stage II (any age) → No OS benefit

💬 Supports an individualized, age- and stage-adapted approach to adjuvant oxaliplatin use

https://t.co/kEszxn4Mq8

[Lorenzo Dottorini @lorenzodotto]

@nicolobattisti @faupe @OncoGeriatria @aluciani73 @giandodm1 @SIOGorg @YoungSIOG @WilliamDale_MD @GrantWilliamsMD @OncBrothers

[Lorenzo Dottorini @lorenzodotto]

Adjuvant CDK4/6 inhibitors in older patients: safe and effective or to be used with caution? We aimed to answer in our last study I'm very happy to share.
As always special thanks to @JGeriOnc staff.

https://t.co/DoJU3mncvg

[Lorenzo Dottorini @lorenzodotto]

A must-read. Congrats to the authors.
@SIOGorg @YoungSIOG

[The Lancet Oncology @TheLancetOncol]

New Policy Review:

Management of #immunecheckpointinhibitor-associated #toxicities in #older adults with #cancer: recommendations from the International Society of Geriatric Oncology @SIOGorg https://t.co/50aGW60szt

[Lorenzo Dottorini @lorenzodotto]

@oncology_bg @Medscape I absolutely agree.
Many examples of studies could be done about this, especially if we talk about older patients. Great job.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Every time they approve a drug based on non-survival endpoint, they give us some excuse. I have collected those excuses. There are seven of them.
In this new column in @Medscape , I and Dr. Sharon Batt, a cancer survivor and regulatory science expert, list these seven arguments and specifically respond to each of them to demonstrate why OS still remains the most patient centric endpoint for cancer drug trials.
Please do read. This is NOT another “surrogates are bad” paper. We specifically address the concerns raised against OS. I hope you’ll be convinced.

https://t.co/KCEmmBudV2

[Lorenzo Dottorini @lorenzodotto]

Outstanding paper! Congrats to @Icro_Meattini and colleagues

https://t.co/xWmxe2tH0B

[Lorenzo Dottorini @lorenzodotto]

@SirRobArtII1 Meeeee my friend 😃😃👍🏻👍🏻

[GIOGER (Gruppo Italiano di Oncologia Geriatrica) @OncoGeriatria]

Young oncologists speaking of Geriatric Oncology issues
AIOTE National Meeting

[GIOGER (Gruppo Italiano di Oncologia Geriatrica) @OncoGeriatria]

First day AIOTE National Meeting Siracusa

[Lorenzo Dottorini @lorenzodotto]

@JGeriOnc @LeanaChien @SunCanlan @DanengLi @WilliamDale_MD @rochgerionc @myCARG Congrats to the authors!

[Lorenzo Dottorini @lorenzodotto]

Outstanding paper! Hospitalized older patients need more attentions! Congrats to the authors

[Journal of Geriatric Oncology @JGeriOnc]

Geriatric Assessment-driven INterventions among Hospitalized older adults with cancer (GAIN-HOSP), a prospective pilot study https://t.co/dOX3mBF4bL @LeanaChien @SunCanlan @DanengLi @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Aging

[International Society of Geriatric Oncology (SIOG) @SIOGorg]

There are just a few days until #ESMO24! We're looking forward to seeing many colleagues and friends. Stop by the #SIOG stand S314 to say hi! Psst. We're offering special ESMO24 discounts on SIOG memberships. Spread the word. See you then!

[Lorenzo Dottorini @lorenzodotto]

Absolute outstanding result!
Once again the demonstration that in older patients sometimes "less is more".
Congrats to the authors.
@SIOGorg @YoungSIOG

[Erman Akkus @Erman_Akkus]

💉FOLFOX/Xelox + beva vs. 5FU/cape +beva in first line treatment of metastatic CRC in older patients
@JCO_ASCO

➡️Median age 80 and 79
❌No difference in PFS, 10 vs 9.4 mo.
❌No difference in OS, 19.7 vs 21.3 mo.
❌grade ≥3 AEs 69% vs. 52%

❗️~65% left sided and ~36% RAS WT

👉https://t.co/TvtQM19Rc6

@JCOOP_ASCO @ASCO @OncoAlert @BbaharK #cancer #oncology #MedX

[Lorenzo Dottorini @lorenzodotto]

Congrats to @faupe and colleagues. Vitamin D supplementation reduce total cancer mortality! Strong evidence for thyroid and renal cancer, highly suggestive evidence for many others. Maybe Vit D is deeply underestimated in oncology treatment and prevention?
https://t.co/UKpLnQhINl